<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">Cardiovascular disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e>) risk is increased in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>The purpose of this study was to assess the effect of 10 mg of <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> versus placebo on <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> prevention in subjects with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and <z:chebi fb="1" ids="47774">LDL cholesterol</z:chebi> levels below contemporary guideline targets </plain></SENT>
<SENT sid="2" pm="."><plain>RESEARCH DESIGN AND METHODS: Subjects were randomly assigned to receive 10 mg of <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> or placebo in a 4-year, double-blind, parallel-group study </plain></SENT>
<SENT sid="3" pm="."><plain>The composite primary end point comprised cardiovascular <z:hpo ids='HP_0011420'>death</z:hpo>, nonfatal <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo>, nonfatal <z:hpo ids='HP_0001297'>stroke</z:hpo>, recanalization, coronary artery bypass surgery, resuscitated <z:hpo ids='HP_0001695'>cardiac arrest</z:hpo>, and worsening or unstable <z:mp ids='MP_0006112'>angina</z:mp> requiring hospitalization </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: A total of 2,410 subjects with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> were randomized </plain></SENT>
<SENT sid="5" pm="."><plain>Mean <z:chebi fb="1" ids="47774">LDL cholesterol</z:chebi> reduction in the <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> group over 4 years was 29% versus placebo (P &lt; 0.0001) </plain></SENT>
<SENT sid="6" pm="."><plain>When we compared <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> versus placebo, composite primary end point rates were 13.7 and 15.0%, respectively (hazard ratio 0.90 [95% CI 0.73-1.12]) </plain></SENT>
<SENT sid="7" pm="."><plain>In the subset of 1,905 subjects without prior <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> or interventional procedure, 10.4% of <z:chebi fb="0" ids="39548">atorvastatin</z:chebi>- and 10.8% of placebo-treated subjects experienced a primary end point (0.97 [0.74-1.28]) </plain></SENT>
<SENT sid="8" pm="."><plain>In the 505 subjects with prior <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> or interventional procedure, 26.2% of <z:chebi fb="0" ids="39548">atorvastatin</z:chebi>- and 30.8% of placebo-treated subjects experienced a primary end point (0.82 [0.59-1.15]) </plain></SENT>
<SENT sid="9" pm="."><plain>Relative risk reductions in fatal and nonfatal <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> were 27% overall (P = 0.10) and 19% (P = 0.41) and 36% (P = 0.11) for subjects without and with prior <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> or interventional procedure, respectively </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: Composite end point reductions were not statistically significant </plain></SENT>
<SENT sid="11" pm="."><plain>This result may relate to the overall study design, the types of subjects recruited, the nature of the primary end point, and the protocol changes required because of changing treatment guidelines </plain></SENT>
<SENT sid="12" pm="."><plain>For these reasons, the results of the <z:chebi fb="0" ids="39548">Atorvastatin</z:chebi> Study for Prevention of <z:e sem="disease" ids="C0010068" disease_type="Disease or Syndrome" abbrv="">Coronary Heart Disease</z:e> Endpoints in Non-<z:hpo ids='HP_0100651'>Insulin-Dependent Diabetes Mellitus</z:hpo> (ASPEN) did not confirm the benefit of therapy but do not detract from the imperative that the majority of diabetic patients are at risk of <z:e sem="disease" ids="C0010068" disease_type="Disease or Syndrome" abbrv="">coronary heart disease</z:e> and deserve <z:chebi fb="1" ids="47774">LDL cholesterol</z:chebi> lowering to the currently recommended targets </plain></SENT>
</text></document>